A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity

Louisa Nelson, Anthony Tighe, Anya Golder, Samantha Littler, Bjorn Bakker, Daniela Moralli, Syed Murtuza Baker, Ian J Donaldson, Diana C J Spierings, René Wardenaar, Bethanie Neale, George J Burghel, Brett Winter-Roach, Richard Edmondson, Andrew R Clamp, Gordon C Jayson, Sudha Desai, Catherine M Green, Andy Hayes, Floris FoijerRobert D Morgan, Stephen S Taylor*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)
119 Downloads (Pure)

Abstract

High-grade serous ovarian carcinoma is characterised by TP53 mutation and extensive chromosome instability (CIN). Because our understanding of CIN mechanisms is based largely on analysing established cell lines, we developed a workflow for generating ex vivo cultures from patient biopsies to provide models that support interrogation of CIN mechanisms in cells not extensively cultured in vitro. Here, we describe a “living biobank” of ovarian cancer models with extensive replicative capacity, derived from both ascites and solid biopsies. Fifteen models are characterised by p53 profiling, exome sequencing and transcriptomics, and karyotyped using single-cell whole-genome sequencing. Time-lapse microscopy reveals catastrophic and highly heterogeneous mitoses, suggesting that analysis of established cell lines probably underestimates mitotic dysfunction in advanced human cancers. Drug profiling reveals cisplatin sensitivities consistent with patient responses, demonstrating that this workflow has potential to generate personalized avatars with advantages over current pre-clinical models and the potential to guide clinical decision making.

Original languageEnglish
Article number822
Number of pages18
JournalNature Communications
Volume11
Issue number1
DOIs
Publication statusPublished - 13-Feb-2020

Keywords

  • CHROMOSOMAL INSTABILITY
  • SEROUS CARCINOMA
  • BREAST-CANCER
  • CELLS
  • CONSEQUENCES
  • CYTOSCAPE
  • OLAPARIB
  • PATHWAY
  • IMPACT

Cite this